Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 165

The DOI matches its Crossref record.

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia

Open access
Badoux, Xavier C., Keating, Michael J., Wen, Sijin, Lee, Bang-Ning, Sivina, Mariela, Reuben, James, Wierda, William G., O'Brien, Susan M., Faderl, Stefan, Kornblau, Steven M., Burger, Jan A., Ferrajoli, Alessandra·2011·Blood

Abstract

The best initial therapy for elderly patients with chronic lymphocytic leukemia (CLL) has not yet been defined. We investigated the activity of lenalidomide as initial therapy for elderly patients with CLL. Sixty patients with CLL 65 years of age and older received treatment with lenalidomide orally 5 mg daily for 56 days, then titrated up to 25 mg/d as tolerated. Treatment was continued until disease progression. At a median follow-up of 29 months, 53 patients (88%) are alive and 32 patients (53%) remain on therapy. Estimated 2-year progression-free survival is 60%. The overall response rate to lenalidomide therapy is 65%, including 10% complete response, 5% complete response with residual cytopenia, 7% nodular partial response, and 43% partial response. Neutropenia is the most common grade 3 or 4 treatment-related toxicity observed in 34% of treatment cycles. Major infections or neutropenic fever occurred in 13% of patients. Compared with baseline levels, we noted an increase in serum immunoglobulin levels across all classes, and a reduction in CCL3 and CCL4 plasma levels was noted in responding patients. Lenalidomide therapy was well tolerated and induced durable remissions in this population of elderly, symptomatic patients with CLL. This study was registered at www.clinicaltrials.gov as #NCT00535873.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2011-03-339077

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 165

Metadata

Authors
Badoux, X. C., Keating, M. J., Wen, S., Lee, B.-N., Sivina, M., Reuben, J., Wierda, W. G., O'Brien, S. M., Faderl, S., Kornblau, S. M., Burger, J. A., & Ferrajoli, A.
Venue
Blood
Published
2011-09-29
Volume
118
Issue
13
Pages
3489-3498
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2100207540
Cited by
165
References
0
FWCI
11.99
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. https://app.cochat.ai/papers/10.1182/blood-2011-03-339077
The paper
Badoux, X. C., Keating, M. J., Wen, S., Lee, B.-N., Sivina, M., Reuben, J., Wierda, W. G., O'Brien, S. M., Faderl, S., Kornblau, S. M., Burger, J. A., & Ferrajoli, A. (2011). Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood. https://doi.org/10.1182/blood-2011-03-339077

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.